Targeted Therapies for Hepatocellular Carcinoma Augusto Villanueva, Josep M. Llovet  Gastroenterology  Volume 140, Issue 5, Pages 1410-1426 (May 2011) DOI: 10.1053/j.gastro.2011.03.006 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 (A) Survival trends of patients with advanced CRC from 1990 to 2005, based on treatment. Those who received a combination of chemotherapy and targeted therapy (an anti-angiogenic agent) had the longest survival times. IFL, irinotecan, bolus of 5-fluorouracil, and leucovorin; FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, irinotecan, infusion of 5-fluorouracil, and leucovorin. (B) Personalized treatment of CRC. In a trial of cetuximab as a second-line therapy for patients with CRC, those with tumors that expressed wild-type KRAS had longer survival times than patients whose tumor cells had KRAS mutations. Data were obtained from 2 studies analyzing a total of 572 patients.118,119 Gastroenterology 2011 140, 1410-1426DOI: (10.1053/j.gastro.2011.03.006) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Individualizing therapy for patients with HCC. Therapeutics might be developed to target factors that contribute to progression of most tumor types (therapeutic approach) and factors required for progression of HCC specifically (oncogene addiction). This approach is used to treat patients with CRC and other types of cancer. Gastroenterology 2011 140, 1410-1426DOI: (10.1053/j.gastro.2011.03.006) Copyright © 2011 AGA Institute Terms and Conditions